Evidence map›Paper›PMID 42391173›Full record

ArticlePloS one2026

Retrospective cohort study of Advanced HIV disease among children and adolescents in Uganda: Characteristics, clinical outcomes, and rate of mortality.

Calvin Epidu, Rogers N Ssebunya, Freddrick E Makumbi, Edgar Sserunkuma, Emmanuel Tumwine, Patrick Kizza, Michael Juma, Henry Balwa, Betty Nsangi, Albert K Maganda and 3 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Calvin EpiduBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Rogers N SsebunyaBaylor College of Medicine Children's Foundation, Kampala, Uganda.ORCID https://orcid.org/0000-0003-1625-1579
Freddrick E MakumbiDepartment of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda.
Edgar SserunkumaBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Emmanuel TumwineBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Patrick KizzaBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Michael JumaBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Henry BalwaBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Betty NsangiBaylor College of Medicine Children's Foundation, Kampala, Uganda.ORCID https://orcid.org/0000-0001-7602-6483
Albert K MagandaBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Denise J BirungiBaylor College of Medicine Children's Foundation, Kampala, Uganda.
Arthur G FitzmauriceDivision of Global HIV & TB, Global Health Center, United States Centers for Disease Control and Prevention, Kampala, Uganda.
Dithan KiraggaBaylor College of Medicine Children's Foundation, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople diagnosed with advanced HIV disease (AHD) are at high risk for mortality even after starting antiretroviral therapy (ART). We determined characteristics, clinical outcomes, and risks of mortality among children and adolescents diagnosed with AHD in western Uganda.

methodsWe conducted a retrospective cohort analysis of routinely collected program data of children and adolescents living with HIV (CALHIV) aged 0-19 years, from outpatient HIV clinic electronic medical records in 48 high-volume health facilities in two regions of western Uganda (Fort Portal and Hoima). Data for clients who initiated ART during January 2016-July 2023 were analysed. AHD was defined as a CD4 cell count <200 cells/μL, or WHO stage 3 or 4, or any child younger than 5 years of age living with HIV who had been on ART for more than 12 months and virally non-suppressed (≥1,000 copies). We used descriptive statistics (i.e., frequencies and percentages) to summarise characteristics and treatment outcomes. Kaplan-Meier curves were used to estimate survival overall and by clients' characteristics; log-rank tests were used to compare survival functions. A gamma-shared frailty model was used to determine factors associated with the rate of mortality. Effect measures were summarized using adjusted hazard ratios (aHRs) with corresponding 95% confidence intervals (95%CI).

resultsA total of 5,143 CALHIV, including 3,067 (59.6%) females, with a median (interquartile range [IQR]) age of 10 (9) years were assessed. Overall, AHD was high (18.1%) and varied by age-0-4 years (68.4%), 5-9 years (12.6%), 10-14 years (13.2%), and lowest among adolescents, 15-19 years (7.7%). Just over half of the CALHIV with AHD were active in care (51.5% [480/932]), about a quarter (26.4% [264/932]) had transferred out, 13.8% (129/932) were lost to follow-up, and 8.3% (77/932) had died. Survival was significantly higher in CALHIV who were not malnourished compared to those with malnutrition (p = 0.001). Overall mortality rate per 100 person-years among CALHIV with AHD was 4.1 (95%CI:3.2-5.2) and was significantly higher among those who had been on ART for 3 months or less (27.3; 95%CI: 20.6-36.2) compared to 6 months or more (1.0; 95%CI: 0.6-1.7).

conclusionAdvanced HIV Disease among CALHIV in western Uganda was consistent with what has been published elsewhere. Risk of death differed by nutrition status and was high among those on ART three months or less. Early screening and management of malnutrition, as well as early ART initiation and adherence initiatives, might improve outcomes and reduce AHD-related mortality among CALHIV.

Indexed as

HIV InfectionsAdolescentAnti-HIV AgentsCD4 Lymphocyte CountChildChild, PreschoolFemaleHumansInfantInfant, NewbornKaplan-Meier EstimateMaleRetrospective StudiesTreatment OutcomeUgandaYoung AdultAnti-HIV Agents

Identifiers

PMID42391173
PMCPMC13327243

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.